Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kJ/mole | IC50 nM | Kd nM | EC50/IC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Plasma kallikrein (Homo sapiens (Human)) | BDBM416718![]() (1-(3-(aminomethyl)phenyl)-N-(2-fluoro-5-(phenyl(pr...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
TBA | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ... | Citation and Details BindingDB Entry DOI: 10.7270/Q2FT8Q7S | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416720![]() (1-(3-(aminomethyl)phenyl)-N-(2-fluoro-3-(phenyl(pr...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
TBA | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ... | Citation and Details BindingDB Entry DOI: 10.7270/Q2FT8Q7S | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416721![]() (Racemic 1-(3-(aminomethyl)phenyl)-N-(3-((cycloprop...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
TBA | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ... | Citation and Details BindingDB Entry DOI: 10.7270/Q2FT8Q7S | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416725![]() (Racemic 1-(3-(aminomethyl)phenyl)-N-(3-((cycloprop...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
TBA | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ... | Citation and Details BindingDB Entry DOI: 10.7270/Q2FT8Q7S | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416730![]() (1-(3-(aminomethyl)phenyl)-N-(3-(3-cyclopropyl-1-ph...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
TBA | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ... | Citation and Details BindingDB Entry DOI: 10.7270/Q2FT8Q7S | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416733![]() (1-(3-(Aminomethyl)phenyl)-N-(3-(((cyclopropylmethy...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
TBA | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ... | Citation and Details BindingDB Entry DOI: 10.7270/Q2FT8Q7S | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416736![]() (1-(3-(aminomethyl)phenyl)-N-(3-((cyclopropylmethox...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
TBA | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ... | Citation and Details BindingDB Entry DOI: 10.7270/Q2FT8Q7S | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416739![]() (1-(3-(aminomethyl)phenyl)-N-(3-((2-cyclopropylethy...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
TBA | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ... | Citation and Details BindingDB Entry DOI: 10.7270/Q2FT8Q7S | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416742![]() (1-(3-(aminomethyl)phenyl)-N-(3-((cyclopropylmethyl...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
TBA | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ... | Citation and Details BindingDB Entry DOI: 10.7270/Q2FT8Q7S | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416745![]() (1-(3-(aminomethyl)phenyl)-N-(3-((cyclopropylmethox...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
TBA | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ... | Citation and Details BindingDB Entry DOI: 10.7270/Q2FT8Q7S | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM528593![]() (US11192861, Compound 34c) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
TBA | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ... | Citation and Details BindingDB Entry DOI: 10.7270/Q2FT8Q7S | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416748![]() (1-(3-(aminomethyl)phenyl)-N-(3-((cyclopropylmethyl...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
TBA | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ... | Citation and Details BindingDB Entry DOI: 10.7270/Q2FT8Q7S | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416751![]() (Racemic 1-(3-(aminomethyl)phenyl)-N-(3-(3-cyclopro...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
TBA | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ... | Citation and Details BindingDB Entry DOI: 10.7270/Q2FT8Q7S | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416757![]() (1-(3-(aminomethyl)phenyl)-N-(3-(3-cyclopropyl-1-(1...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
TBA | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ... | Citation and Details BindingDB Entry DOI: 10.7270/Q2FT8Q7S | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM439345![]() (US10633345, Compound 91a | US10689346, Compound 91...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
TBA | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ... | Citation and Details BindingDB Entry DOI: 10.7270/Q2FT8Q7S | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM439347![]() (US10633345, Compound 41e | US10689346, Compound 41...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
TBA | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ... | Citation and Details BindingDB Entry DOI: 10.7270/Q2FT8Q7S | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM528609![]() (US11192861, Compound 86g) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
TBA | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ... | Citation and Details BindingDB Entry DOI: 10.7270/Q2FT8Q7S | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM528611![]() (US11192861, Compound 74a) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
TBA | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ... | Citation and Details BindingDB Entry DOI: 10.7270/Q2FT8Q7S | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416767![]() (1-(3-(aminomethyl)phenyl)-N-(3-(3-cyclopropyl-1-hy...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
TBA | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ... | Citation and Details BindingDB Entry DOI: 10.7270/Q2FT8Q7S | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416770![]() (Racemic 1-(3-(aminomethyl)phenyl)-N-(3-(3-cyclopro...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
TBA | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ... | Citation and Details BindingDB Entry DOI: 10.7270/Q2FT8Q7S | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416773![]() (1-(3-(aminomethyl)phenyl)-N-(5-(((cyclopropylmethy...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
TBA | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ... | Citation and Details BindingDB Entry DOI: 10.7270/Q2FT8Q7S | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416774![]() (1-(3-(aminomethyl)phenyl)-N-(3-(3-cyclopropyl-1-hy...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
TBA | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ... | Citation and Details BindingDB Entry DOI: 10.7270/Q2FT8Q7S | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416775![]() (1-(3-(aminomethyl)phenyl)-N-(3-((cyclopropylmethox...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
TBA | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ... | Citation and Details BindingDB Entry DOI: 10.7270/Q2FT8Q7S | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416777![]() (1-(3-(aminomethyl)phenyl)-N-(3-(((cyclopropylmethy...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
TBA | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ... | Citation and Details BindingDB Entry DOI: 10.7270/Q2FT8Q7S | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416779![]() (1-(3-(aminomethyl)phenyl)-N-(3-((cyclopropylmethox...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
TBA | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ... | Citation and Details BindingDB Entry DOI: 10.7270/Q2FT8Q7S | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416780![]() (1-(3-(aminomethyl)phenyl)-N-(3-((cyclopropylmethyl...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
TBA | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ... | Citation and Details BindingDB Entry DOI: 10.7270/Q2FT8Q7S | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416782![]() (1-(3-(Aminomethyl)phenyl)-N-(3-((cyclopropylmethyl...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
TBA | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ... | Citation and Details BindingDB Entry DOI: 10.7270/Q2FT8Q7S | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416783![]() (2-(3-Aminomethyl-phenyl)-5-trifluoromethyl-2H-pyra...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
TBA | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ... | Citation and Details BindingDB Entry DOI: 10.7270/Q2FT8Q7S | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416784![]() (1-(3-(aminomethyl)phenyl)-N-(5-((cyclopropylmethyl...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
TBA | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ... | Citation and Details BindingDB Entry DOI: 10.7270/Q2FT8Q7S | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416785![]() (1-(3-(Aminomethyl)phenyl)-N-(3-((cyclopropylmethyl...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
TBA | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ... | Citation and Details BindingDB Entry DOI: 10.7270/Q2FT8Q7S | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416786![]() (2-(3-Aminomethyl-phenyl)-5-trifluoromethyl-2H-pyra...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
TBA | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ... | Citation and Details BindingDB Entry DOI: 10.7270/Q2FT8Q7S | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM439372![]() (US10633345, Compound 95i | US10689346, Compound 95...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
TBA | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ... | Citation and Details BindingDB Entry DOI: 10.7270/Q2FT8Q7S | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416788![]() (1-(3-(Aminomethyl)phenyl)-N-(3-((cyclopropylmethyl...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
TBA | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ... | Citation and Details BindingDB Entry DOI: 10.7270/Q2FT8Q7S | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416792![]() (1-(3-(aminomethyl)phenyl)-N-(5-((3-aminophenyl)(cy...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
TBA | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ... | Citation and Details BindingDB Entry DOI: 10.7270/Q2FT8Q7S | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416790![]() (1-(3-(Aminomethyl)phenyl)-N-(2-chloro-5-((cyclopro...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
TBA | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ... | Citation and Details BindingDB Entry DOI: 10.7270/Q2FT8Q7S | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416791![]() (1-(3-(aminomethyl)phenyl)-N-(3-((cyclopropylmethyl...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
TBA | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ... | Citation and Details BindingDB Entry DOI: 10.7270/Q2FT8Q7S | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416792![]() (1-(3-(aminomethyl)phenyl)-N-(5-((3-aminophenyl)(cy...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
TBA | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ... | Citation and Details BindingDB Entry DOI: 10.7270/Q2FT8Q7S | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416794![]() (Racemic 1-(3-(aminomethyl)phenyl)-N-(5-((cycloprop...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
TBA | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ... | Citation and Details BindingDB Entry DOI: 10.7270/Q2FT8Q7S | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416795![]() (1-(3-(aminomethyl)phenyl)-N-(3-((cyclopropylmethyl...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
TBA | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ... | Citation and Details BindingDB Entry DOI: 10.7270/Q2FT8Q7S | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416796![]() (1-(3-(aminomethyl)phenyl)-N-(5-(((cyclopropylmethy...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
TBA | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ... | Citation and Details BindingDB Entry DOI: 10.7270/Q2FT8Q7S | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416797![]() (1-(3-(aminomethyl)phenyl)-N-(5-fluoro-2-methyl-1,2...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
TBA | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ... | Citation and Details BindingDB Entry DOI: 10.7270/Q2FT8Q7S | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416798![]() (1-(3-(aminomethyl)phenyl)-N-(3-((cyclopropylmethyl...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
TBA | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ... | Citation and Details BindingDB Entry DOI: 10.7270/Q2FT8Q7S | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416799![]() (2-(3-Aminomethyl-phenyl)-5-trifluoromethyl-2H-pyra...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
TBA | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ... | Citation and Details BindingDB Entry DOI: 10.7270/Q2FT8Q7S | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416804![]() (2-(3-Aminomethyl-phenyl)-5-trifluoromethyl-2H-pyra...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
TBA | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ... | Citation and Details BindingDB Entry DOI: 10.7270/Q2FT8Q7S | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM439390![]() (US10633345, Compound 98b | US10689346, Compound 98...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
TBA | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ... | Citation and Details BindingDB Entry DOI: 10.7270/Q2FT8Q7S | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416807![]() (1-(3-(aminomethyl)phenyl)-N-(3-((cyclopropylmethyl...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
TBA | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ... | Citation and Details BindingDB Entry DOI: 10.7270/Q2FT8Q7S | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416808![]() (1-(3-(aminomethyl)phenyl)-N-(3-(((cyclopropylmethy...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
TBA | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ... | Citation and Details BindingDB Entry DOI: 10.7270/Q2FT8Q7S | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416809![]() (1-(3-(aminomethyl)phenyl)-N-(3-(2-(cyclopropylamin...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
TBA | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ... | Citation and Details BindingDB Entry DOI: 10.7270/Q2FT8Q7S | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416810![]() (1-(3-(aminomethyl)phenyl)-N-(3-((cyclopropylmethyl...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
TBA | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ... | Citation and Details BindingDB Entry DOI: 10.7270/Q2FT8Q7S | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasma kallikrein (Homo sapiens (Human)) | BDBM416812![]() (1-(3-(aminomethyl)phenyl)-N-(5-((cyclopropylmethyl...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
TBA | Assay Description The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates (DiaPharma Group, Inc., ... | Citation and Details BindingDB Entry DOI: 10.7270/Q2FT8Q7S | |||||||||||
More data for this Ligand-Target Pair |
Displayed 1 to 50 (of 302 total ) | Next | Last >> |